Correlation Between Neuropace and Xtant Medical
Can any of the company-specific risk be diversified away by investing in both Neuropace and Xtant Medical at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Neuropace and Xtant Medical into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Neuropace and Xtant Medical Holdings, you can compare the effects of market volatilities on Neuropace and Xtant Medical and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Neuropace with a short position of Xtant Medical. Check out your portfolio center. Please also check ongoing floating volatility patterns of Neuropace and Xtant Medical.
Diversification Opportunities for Neuropace and Xtant Medical
-0.83 | Correlation Coefficient |
Pay attention - limited upside
The 3 months correlation between Neuropace and Xtant is -0.83. Overlapping area represents the amount of risk that can be diversified away by holding Neuropace and Xtant Medical Holdings in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Xtant Medical Holdings and Neuropace is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Neuropace are associated (or correlated) with Xtant Medical. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Xtant Medical Holdings has no effect on the direction of Neuropace i.e., Neuropace and Xtant Medical go up and down completely randomly.
Pair Corralation between Neuropace and Xtant Medical
If you would invest 134.00 in Neuropace on September 14, 2024 and sell it today you would earn a total of 957.00 from holding Neuropace or generate 714.18% return on investment over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Against |
Strength | Significant |
Accuracy | 100.0% |
Values | Daily Returns |
Neuropace vs. Xtant Medical Holdings
Performance |
Timeline |
Neuropace |
Xtant Medical Holdings |
Neuropace and Xtant Medical Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Neuropace and Xtant Medical
The main advantage of trading using opposite Neuropace and Xtant Medical positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Neuropace position performs unexpectedly, Xtant Medical can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Xtant Medical will offset losses from the drop in Xtant Medical's long position.Neuropace vs. Electromed | Neuropace vs. Orthopediatrics Corp | Neuropace vs. SurModics | Neuropace vs. Paragon 28 |
Xtant Medical vs. Avita Medical | Xtant Medical vs. Sight Sciences | Xtant Medical vs. Treace Medical Concepts | Xtant Medical vs. Neuropace |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Other Complementary Tools
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Bonds Directory Find actively traded corporate debentures issued by US companies |